Ghaziabad Online

BK virus Infection Pipeline Insights and Emerging Therapies 2021 by DelveInsight

 Breaking News
  • No posts were found

BK virus Infection Pipeline Insights and Emerging Therapies 2021 by DelveInsight

March 05
21:14 2021
BK virus Infection Pipeline Insights and Emerging Therapies 2021 by DelveInsight

 

DelveInsight has launched a new report on BK virus Infection Pipeline

 

BK Virus (BKV) Infection also known as polyomavirus is a member of the human polyomavirus family. BKV resides dormant in uroepithelial cells as it is mostly acquired in childhood and is not known to cause tissue damage in immunocompetent individuals. The virus can become reactivated in case of immunodeficiency (e.g., secondary to HIV infection or immunosuppressive medications), and result in cellular damage and organ dysfunction.

 

Browse for free sample copyhttps://www.delveinsight.com/sample-request/bk-virus-bkv-infection-pipeline-insight

 

BK virus Infection Pipeline analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of BK virus Infection Pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities

 

BK virus Infection Pipeline

The kidney, lung, eye, liver, and brain are sites of BK virus-associated disease, both primary and reactivated. BK virus infection in the kidney manifests as hemorrhagic cystitis, ureteric stenosis, nephritis and others. Pulmonary diseases that involve BK virus include pneumonitis and acute nonspecific upper respiratory tract infection.

In transplant recipients, however, BKV reactivation is common and can lead to distinctive pathological entities in different patient groups such as in renal transplant (RT) recipients, it is associated with nephropathy (BKVN) and ureteral stenosis, and in hematopoietic stem cell transplant (HSCT) recipients with hemorrhagic cystitis (HC).

 

BK virus Infection Symptoms

The symptoms of the infection include changes in vision and color of your urine (urine that is brown or red in color), pain while urinating, increase in urination frequency, cough, cold or trouble breathing, fever, muscle pain or weakness, seizures.

Unfortunately, there are no marketed drugs for this infection and the mainstay of managing reactivation is by immunosuppression, which is achieved by discontinuation of an agent, decreasing an agent, switching immunosuppressant within the same or another class, and steroid avoidance.

 

Emerging drugs included in the report

  • Viralym-M (ALVR105): AlloVir
  • MAU868: Amplyx Pharmaceuticals

 

BK virus Infection Emerging Drugs

The dynamics of the BK Virus (BKV) Infection market is anticipated to change in the coming years owing to the improvement in the research and development. The launch of emerging therapies is expected during the forecast period of 2021–2030.

 

BK virus Infection Report Scope

  • The BK virus (BKV) Infection report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for BK virus (BKV) Infection across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of BK virus (BKV) Infection therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed BK virus (BKV) Infection research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across BK virus (BKV) Infection.

 

Table of content

1. Report Introduction

2. BK virus (BKV) Infection 

3. BK virus (BKV) Infection Current Treatment Patterns

4. BK virus (BKV) Infection – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. BK virus (BKV) Infection Late Stage Products (Phase-III)

7. BK virus (BKV) Infection Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. BK virus (BKV) Infection Discontinued Products

13. BK virus (BKV) Infection Product Profiles

14. BK virus (BKV) Infection Key Companies

15. BK virus (BKV) Infection Key Products

16. Dormant and Discontinued Products

17. BK virus (BKV) Infection Unmet Needs

18. BK virus (BKV) Infection Future Perspectives

19. BK virus (BKV) Infection Analyst Review  

20. Appendix

21. Report Methodology

 

Browse for free sample copy– https://www.delveinsight.com/sample-request/bk-virus-bkv-infection-pipeline-insight

 

 

What are the report highlights?

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for BK virus (BKV) Infection.   
  • In the coming years, the BK virus (BKV) Infection market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence BK virus (BKV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the BK virus (BKV) Infection treatment market. Several potential therapies for BK virus (BKV) Infection are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the BK virus (BKV) Infection market size in the coming years. 
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of BK virus (BKV) Infection) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share